1. Home
  2. GMAB vs SNA Comparison

GMAB vs SNA Comparison

Compare GMAB & SNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMAB
  • SNA
  • Stock Information
  • Founded
  • GMAB 1999
  • SNA 1920
  • Country
  • GMAB Denmark
  • SNA United States
  • Employees
  • GMAB N/A
  • SNA N/A
  • Industry
  • GMAB Biotechnology: Pharmaceutical Preparations
  • SNA Industrial Machinery/Components
  • Sector
  • GMAB Health Care
  • SNA Consumer Discretionary
  • Exchange
  • GMAB Nasdaq
  • SNA Nasdaq
  • Market Cap
  • GMAB 17.4B
  • SNA 18.1B
  • IPO Year
  • GMAB N/A
  • SNA N/A
  • Fundamental
  • Price
  • GMAB $30.40
  • SNA $342.09
  • Analyst Decision
  • GMAB Strong Buy
  • SNA Buy
  • Analyst Count
  • GMAB 6
  • SNA 5
  • Target Price
  • GMAB $40.40
  • SNA $361.00
  • AVG Volume (30 Days)
  • GMAB 2.6M
  • SNA 341.8K
  • Earning Date
  • GMAB 11-06-2025
  • SNA 10-16-2025
  • Dividend Yield
  • GMAB N/A
  • SNA 2.50%
  • EPS Growth
  • GMAB 132.41
  • SNA N/A
  • EPS
  • GMAB 25.10
  • SNA 19.06
  • Revenue
  • GMAB $3,845,670,022.00
  • SNA $5,115,400,000.00
  • Revenue This Year
  • GMAB $24.92
  • SNA N/A
  • Revenue Next Year
  • GMAB $15.97
  • SNA $3.42
  • P/E Ratio
  • GMAB $1.21
  • SNA $17.99
  • Revenue Growth
  • GMAB 29.57
  • SNA 0.24
  • 52 Week Low
  • GMAB $17.24
  • SNA $289.81
  • 52 Week High
  • GMAB $33.65
  • SNA $373.90
  • Technical
  • Relative Strength Index (RSI)
  • GMAB 57.24
  • SNA 53.77
  • Support Level
  • GMAB $28.08
  • SNA $338.12
  • Resistance Level
  • GMAB $29.35
  • SNA $346.02
  • Average True Range (ATR)
  • GMAB 0.69
  • SNA 5.69
  • MACD
  • GMAB -0.07
  • SNA 0.07
  • Stochastic Oscillator
  • GMAB 98.73
  • SNA 65.71

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

About SNA Snap-On Incorporated

Snap-on is a manufacturer of premium tools, equipment, and diagnostics for professional technicians, primarily involved in the repair of passenger cars, but has expanded into other industrial applications. The company's legacy business is selling hand tools through franchisee-operated mobile vans to technicians who purchase the tools at their own expense. The company also operates a commercial and industrial business, focusing on repair facilities that serve other industries. The third segment, repair systems and information, targets auto OEMs and large dealerships more directly, also offering substantial diagnostic solutions to aid in repairs. The company's finance arm provides financing to franchisees to support their operations, as well as underwrites end-customer purchases.

Share on Social Networks: